Abstract:The GPR52, a class A orphan G protein-coupled receptor (GPCR), is regarded as a promising therapeutic target for the treatment of Huntington's disease and multiple psychiatric disorders. Although the recently solved structure of GPR52 has revealed a binding mechanism likely shared by all reported agonists, the small molecule antagonist E7 cannot fit into this agonist-binding pocket, and its interaction mode with the receptor remains unknown. Here, we employed targeted proteomics and affinity mass spectrometry approaches to uncover a unique binding mode of E7 which acts as a covalent and allosteric ligand of GPR52. Among three Cys residues identified in this study to form covalent conjugates with E7, the intracellular C156<sup>4.40</sup> makes the most significant contribution to the antagonism activity of E7. Discovery of this novel intracellular site for covalent attachment of an antagonist would facilitate the design of GPR52-selective negative allosteric modulators which could serve as potential therapeutics for treating Huntington's disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acschembio.0c00867?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acschembio.0c00867</a>.(Figure S1) Purification of the GPR52 protein; (Figure S2) structure and cell activity of a newly synthesized GPR52 antagonist (Comp-43); (Figure S3) E7 is covalently conjugated to GPR52 expressed in live cells; (Figure S4) molecular docking of reported agonists into the agonist-binding side pocket in the GPR52 structure; (Figure S5) surface expression levels of WT and mutant GPR52 as determined by FACS staining of HEK293/HA-GPR52 cells; (Table S1) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from purified GPR52 protein; (Table S2) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from GPR52 in live cells; (Table S3) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from purified GPR52 protein pretreated with or without 7m (<a class="ext-link" href="/doi/suppl/10.1021/acschembio.0c00867/suppl_file/cb0c00867_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington’s Disease-Related Phenotypes

A Striatal-Enriched Intronic GPCR Modulates Huntingtin Levels and Toxicity

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Protective role of downregulation in Huntington’s Disease models

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide

Targeted Proteomics Combined with Affinity Mass Spectrometry Analysis Reveals Antagonist E7 Acts As an Intracellular Covalent Ligand of Orphan Receptor GPR52

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study

Regulation of P-glycoprotein expression in brain capillaries in Huntington’s disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

CGS21680 Attenuates Symptoms of Huntington's Disease in a Transgenic Mouse Model

Reduction in PA28αβ activation in HD mouse brain correlates to increased mHTT aggregation in cell models

A New Drug Design Targeting The Adenosinergic System For Huntington'S Disease

Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington's Disease